Concomitant osimertinib and antituberculosis therapy in an elderly patient with EGFR‐mutated lung cancer and pulmonary tuberculosis: A case report

Abstract

Abstract The concurrent incidence of lung cancer and tuberculosis is expected to escalate due to the projected growth in the older population. Combination therapy with osimertinib and antituberculosis drugs has not been well‐established. We report a case of successful treatment involving the concomitant administration of osimertinib and antituberculosis drugs in an older patient, an 89‐year‐old female, diagnosed with epidermal growth factor receptor (EGFR)‐mutant lung cancer and pulmonary tuberculosis. Accumulating evidence is warranted to develop an optimal treatment strategy for patients with lung cancer and tuberculosis.

Keywords

• case report
• EGFR‐mutated lung cancer
• osimertinib
• pulmonary tuberculosis
• rifampicin